Registry for patients with advanced metastatic colorectal cancer
AGMT Metastatic Colorectal Cancer Registry (mCRC) Third Line and Beyond
This study is collecting information from patients with advanced colorectal cancer who have tried different treatments to see how well they are doing and to help improve future care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Arbeitsgemeinschaft medikamentoese Tumortherapie Academic / other |
| Locations | 7 sites (Linz and 6 other locations) |
| Trial ID | NCT06678919 on ClinicalTrials.gov |
What this trial studies
This registry aims to evaluate the treatment landscape and clinical outcomes of patients with metastatic colorectal cancer (mCRC) who have received at least two lines of therapy. It will collect data from multiple oncologic centers in Austria, focusing on patients in the third line of therapy and beyond. Information will be gathered from existing medical charts, including treatment history, survival data, and tumor progression. Additionally, imaging studies and tumor tissue samples will be stored for future research, while maintaining patient confidentiality throughout the process.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with a tissue-based diagnosis of metastatic colorectal cancer who have undergone at least two prior lines of palliative systemic therapy.
Not a fit: Patients who have not received at least two lines of therapy or those with a different cancer diagnosis will not benefit from this registry.
Why it matters
Potential benefit: If successful, this registry could provide valuable insights into treatment outcomes and improve future therapeutic strategies for patients with advanced mCRC.
How similar studies have performed: Other studies have shown success in utilizing registries to evaluate treatment outcomes in cancer patients, indicating that this approach is both valid and beneficial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients ≥ 18 years with tissue-based diagnosis of mCRC * ≥ 2 prior lines of palliative systemic therapy including 5-FU, irinotecan, oxaliplatin, anti-VEGF, anti-EGFR (in case of RAS/BRAF wildtype), anti-PD1- therapy (in case of MSI/MMRd) . (Exception: Patients who have received mFOLFOXIRI +/- anti-VEGF or anti- EGFR- 1L therapy or patients with ineligibility to receive 5-FU, oxaliplatin or irinotecan can be included after 1st line.) Exclusion Criteria: * Due to the non-interventional design of this registry, there are no specific exclusion criteria
Where this trial is running
Linz and 6 other locations
- Ordensklinikum Linz, BHS - Interne I — Linz, Austria (Recruiting)
- KUK Linz - Med Campus III.: Univ.-Klinik für Hämatologie und Internistische Onkologie — Linz, Austria (Recruiting)
- LKH Feldkirch: Innere Medizin II/ Interne E (Hämatologie und Onkologie) — Rankweil, Austria (Recruiting)
- Department of Internal Medicine III, Paracelsus Medical University Salzburg — Salzburg, Austria (Recruiting)
- Klinikum Steyr: Innere Medizin II: Onkologie, Gastroenterologie, Angiologie — Steyr, Austria (Recruiting)
- Klinikum Wels: Abteilung für Innere Medizin IV — Wels, Austria (Recruiting)
- KH Zams: Innere Medizin Internistische Onkologie und Hämatologie — Zams, Austria (Recruiting)
Study contacts
- Study coordinator: Daniela Wolkersdorfer, Dr.
- Email: office@agmt.at
- Phone: +436626404412
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.